Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10335470

    Immunogenic compositions comprising progastrin and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10335463

    Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10335404

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10335458

    Pharmaceutical compositions for treating or preventing bone conditions

    The Regents of the University of California · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10335440

    Direct-fed microbials

    MICROBIAL DISCOVERY GROUP, LLC · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10335426

    N-acetyl mannosammine as a therapeutic agent

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10337005

    Oligonucleotide-based inhibitors comprising locked nucleic acid motif

    MIRAGEN THERAPEUTICS, INC. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10335382

    Use of hydrogen sulfide synthesis inhibitors for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10335368

    Ultrasound-triggerable agents for tissue engineering

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10335391

    Stabilized oxymetazoline formulations and their uses

    Aclaris Therapeutics, Inc. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10337010

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10337029

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10336773

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10336833

    Conjugated anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10335402

    Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10335460

    IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions

    THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10335365

    Bladder cancer specific ligand peptides

    The United States of America as represented by the Department of Veteran Affairs (Washington DC) · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10335423

    Inhibition of HIV infection through chemoprophylaxis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10336786

    Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway

    The Board of Regents of the University of Texas System · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10337003

    Compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10336864

    Production method for poly(amino acid)

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10344281

    Functionally-modified oligonucleotides and subunits thereof

    Sarepta Therapeutics, Inc. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10343995

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10342876

    Process for reducing subvisible particles in a pharmaceutical formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10344040

    Pyridone and aza-pyridone compounds and methods of use

    GILEAD CONNECTICUT, INC. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10342764

    Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

    Oramed Ltd. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10342771

    Creatine oral supplementation using creatine hydrochloride salt

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10342786

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10342815

    GLA monotherapy for use in cancer treatment

    IMMUNE DESIGN CORP. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10342791

    Regimens of tafenoquine for prevention of malaria in malaria-naive subjects

    The United States of America as represented by the Secretary of the Army · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10342776

    Compositions and methods for controlling infections

    Regents of the University of Minnesota · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10342804

    Steroid compound for use in the treatment of hepatic encephalopathy

    Umecrine Cognition AB · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10342822

    Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system

    The Board of Regents of the University of Texas System · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10342869

    Compositions comprising anti-CD38 antibodies and lenalidomide

    The Regents of the University of California · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10342867

    Adjuvants

    LITEVAX B.V. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10342871

    Compositions containing nucleosides and manganese and their uses

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10342882

    TCO conjugates and methods for delivery of therapeutic agents

    The Regents of the University of California · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10344027

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10343903

    Cationic polymer coated mesoporous silica nanoparticles and uses thereof

    The Regents of the University of California · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10343981

    Modulators of the eIF2alpha pathway

    The Regents of the University of California · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10344025

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10344033

    2-aminoquinazoline derivatives as P70S6 kinase inhibitors

    SENTINEL ONCOLOGY LIMITED · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10344078

    Type III secretion system targeting molecules

    Inhibrx, Inc. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10344061

    Peptide exhibiting hair growth promoting activity and/or melanin production promoting activity and use thereof

    CAREGEN CO., LTD. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10344064

    Engineered potent cytotoxic stapled BH3 peptides

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10344271

    Modified zinc finger binding proteins

    Sangamo Therapeutics, Inc. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10345310

    Diagnostic test for early stage cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10344096

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    The Regents of the University of California · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.